Unlocking the Mysteries of GI Cancer & Finding Hope
Friday 21 May 2021
11:00am – 11:45am (AEST)
GI cancers are notoriously hard to treat, so what insights have led to survival rates improving over the past 30 years? And what hope does the future hold?
In our 30th anniversary year, join us as we take a look back at how a GI cancer patient’s experience has changed over the years and what we’ve learned about treating GI cancers. We’ll also explore the exciting discoveries currently being tested which could radically change treatments in the future.
Dr Lorraine Chantrill, GI Cancer Institute Chair, is our webinar host and will lead the conversation with our expert guest speakers, prominent GI cancer researchers Professor John Zalcberg OAM and Associate Professor Jeanne Tie.
Discussion will include:
- How treatment can be personalised to a patient’s individual genetic profile
- How can we harness the power of the immune system for GI cancers
- Exciting new treatments like ctDNA blood tests which can detect cancer in the bloodstream
It’s free to register and questions from the audience are encouraged.
Don’t miss your chance to attend and ask questions of these leading GI cancer experts.
Dr Lorraine Chantrill, Chair of the GI Cancer Institute
Dr Chantrill is a Senior Staff Specialist Medical Oncologist and Head of Service for Medical Oncology across the Illawarra Shoalhaven Local Health District (ISLHD), and Area Clinical Director of Clinical Trials. Dr Chantrill treats patients with any cancers of the digestive tract as well as gynaecological cancers and lung cancers. She is a key opinion leader and expert in the field of pancreas cancer. Lorraine completed a PhD by research in the Pancreas Cancer Group at The Kinghorn Cancer Centre in pancreas cancer genomics. Lorraine continues to be an active clinician researcher trying to bridge the gap between the bench and the bedside. She has extensive experience managing Oncology Clinical Trials and is the Principal Investigator on several clinical trials in gastrointestinal cancers.
Professor John Zalcberg, Professor of Cancer Research at Monash University and a Founder of the GI Cancer Institute
Professor John Zalcberg OAM was a founder and is a past Chair of the Board of the GI Cancer Institute. He served in the Chair role for over 18 years until May 2014. He was the Director, Division of Cancer Medicine, at the Peter MacCallum Cancer Centre in Melbourne, Australia for 17 years prior to taking up the position of Professor of Cancer Research at Monash University. Professor Zalcberg’s clinical research interests include gastro-intestinal cancer and health care outcomes. He has published more than 230 articles in peer-reviewed journals.
Associate Professor Jeanne Tie, GI oncology and Trials Lead at Peter MacCallum Cancer Centre
Associate Professor Jeanne Tie is the lower gastrointestinal medical oncology and trials lead at the Peter MacCallum Cancer Centre and senior research fellow in the Personalised Oncology Division at the Walter and Eliza Hall Institute of Medical Research. Her translational research focusses on personalising treatment for patients with colorectal cancer with prognostic and predictive biomarkers, in particular the clinical applications of circulating tumour DNA (ctDNA). She leads several ctDNA-based randomized clinical trials in colorectal cancer which aim to assess the clinical utility of ctDNA in guiding adjuvant treatment decision.
About the GI Cancer Institute
The GI Cancer Institute is a not-for-profit charity dedicated to improving the health and quality of life of patients with Gastro-Intestinal (GI) cancer by developing and conducting impartial and collaborative multi-disciplinary clinical trials which include health professionals, patients and consumers.
GI cancer includes the digestive organs: oesophagus, stomach, liver, gallbladder and biliary tract, pancreas, large and small bowel, rectum and anus. Together these cancers are the most common forms of cancer, with 28,600 Australians diagnosed every year and claiming a devastating 39 lives a day.
The GI Cancer Institute works to raise funds and awareness of GI cancer and clinical trials, and through its AGITG members it develops and delivers rigorous best practice clinical trials for Gastro-Intestinal cancer patients. The AGITG membership encompasses a wide range of medical specialists, scientists, nurses, allied health professionals and consumers involved in all aspects of Gastro-Intestinal cancer research.